Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses
Canopy Growth (TSX: WEED, Nasdaq: CGC) reported Q1 FY2027 results for the three months ended June 30, 2026. Consolidated net revenue rose 13% to C$81.2M, with growth across Canada medical, Canada adult-use, and international. Adjusted gross margin increased to 31% and the adjusted EBITDA loss narrowed 59% to C$3.2M. Free cash outflow widened to C$25.7M.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectations for profitability trajectory (adjusted gross margin and adjusted EBITDA) while monitoring cash-flow sustainability given the increase in free cash outflow.
Market read
A fresh quarterly earnings release with quantified margin and EBITDA improvement, plus explicit drivers (integration, VAC reimbursement) and a cash-flow deterioration that may temper the bullish read-through.
What to watch
VAC reimbursement rate reduction is a recurring headwind; also adjusted gross margin excludes inventory step-up charges, so headline gross margin may understate or overstate underlying trends depending on normalization.
Background
Canopy Growth (CGC) released Q1 FY2027 financial results for the three months ended June 30, 2026, emphasizing progress from MTL Cannabis integration.
Ticker impact
Canopy Growth reports Q1 FY2027 results with 13% consolidated net revenue growth, adjusted gross margin up to 31%, and adjusted EBITDA loss narrowing 59% YoY.
Near-term bias modestly positive on margin/EBITDA improvement, but investors may discount due to larger free cash outflow.
The article provides multiple directionally favorable operating metrics (revenue growth, adjusted gross margin, adjusted EBITDA loss narrowing) plus a clear cash-flow deterioration (free cash outflow rising to $25.7M).
Market effects
Signals ongoing consolidation benefits in Canadian medical cannabis and potential margin normalization, but highlights policy reimbursement risk (VAC rate reduction).
Canada medical and adult-use growth is partly integration-driven, while Europe strength (Poland) supports international momentum.
International revenue growth remains smaller than Canada, so global impact is secondary to Canadian regulatory and reimbursement dynamics.
Counterpoint
Despite margin and adjusted EBITDA improvement, the larger free cash outflow suggests earnings quality may be weaker and could pressure valuation if cash burn persists.
Key entities
- companyCanopy Growth Corporation
Reports Q1 FY2027 consolidated net revenue growth, margin improvement, and narrowing adjusted EBITDA loss, with cash outflow worsening.
- companyMTL Cannabis Corp.
Integration is cited as a driver of higher supply, revenue opportunities, and synergies, and as the source of inventory step-up charges affecting adjusted gross margin comparisons.
- government programVeterans Affairs Canada (VAC)
Reduction in VAC reimbursement rate for medical cannabis is cited as partially offsetting medical cannabis revenue growth and impacting adjusted EBITDA.
